In those with adenocarcinomas, median survival was 58 months in the low CD8+ T cell infiltration group and was not reached in the high infiltration group (HR: 0.262 [95% CI: 0.05510,0.9283]) (Figure 1d). The gene discussed is CD8A; the disease is adenocarcinoma.